Learning from failure: congestive heart failure in the postgenomic age

AUTOR(ES)

Benjamin, Ivor J.

FONTE

American Society for Clinical Investigation

RESUMO

The prognosis of heart failure is worse than that of most cancers, but new therapeutic interventions using stem and other cell-based therapies are succeeding in the fight against it, and old drugs, with new twists, are making a comeback. Genetically engineered animal models are driving insights into the molecular mechanisms that cause hearts to fail, accelerating drug discoveries, and inspiring cell-based therapeutic interventions for both acquired and inheritable cardiac diseases.

Documentos Relacionados

• Mortality in congestive heart failure: effects of vasodilator therapy.
• Treating relentlessly progressive congestive heart failure: what next?
• Ventricular arrhythmias in congestive heart failure: clinical significance and management.
• Breathing disorders in congestive heart failure: gender, etiology and mortality
• Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences.